Spyre Therapeutics, Inc. — Director's Dealing 2017

Sep 1, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-08-31

Reporting Person: Quinn Anthony G. (Director, Interim CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-31	Employee Stock Option (right to buy)	$4.11	A	150000	Acquired	2027-08-30	Common Stock (150000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date.